4//SEC Filing
Farley Chele Chiavacci 4
Accession 0001493152-23-033793
CIK 0001896212other
Filed
Sep 25, 8:00 PM ET
Accepted
Sep 26, 5:49 PM ET
Size
8.1 KB
Accession
0001493152-23-033793
Insider Transaction Report
Form 4
Farley Chele Chiavacci
Director
Transactions
- Award
Warrants
2023-09-22$11.50/sh+15,000$172,500→ 15,000 totalExercise: $11.50Exp: 2028-10-22→ Shares (15,000 underlying) - Award
Common Stock, par value $0.0001 per share ("Shares")
2023-09-22+15,000→ 15,000 total
Footnotes (2)
- [F1]Includes 15,000 shares of common stock of the Company and 15,000 redeemable warrants that Murphy Canyon Acquisition Sponsor, LLC transferred to Ms. Farley in consideration for her acting as an independent director of the Company. Such Shares and warrants were transferred to Mr. Farley immediately after the closing of the business combination contemplated by the Agreement and Plan of Merger, dated as of November 8, 2022 and as amended on January 27, 2023 and May 11, 2023 (the "Merger Agreement"), by and among the Company, Conduit Pharmaceuticals Limited, a Cayman Islands exempted company ("Conduit") and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly-owned subsidiary of MURF (the "Merger Sub"). As a result of, and upon consummation of the transactions contemplated by, the Merger Agreement, the Company changed its name from "Murphy Canyon Acquisition Corp." to "Conduit Pharmaceuticals Inc."
- [F2]The redeemable warrants become exercisable 30 days after the completion of the business combination contemplated by the Merger Agreement, which occurred on September 22, 2023. Accordingly, the redeemable warrants become exercisable on October 22, 2023 and expire on October 22, 2028.
Documents
Issuer
CONDUIT PHARMACEUTICALS INC.
CIK 0001896212
Entity typeother
Related Parties
1- filerCIK 0001908750
Filing Metadata
- Form type
- 4
- Filed
- Sep 25, 8:00 PM ET
- Accepted
- Sep 26, 5:49 PM ET
- Size
- 8.1 KB